Centers for Common Disease Genomics

The Centers for Common Disease Genomics (CCDG) are a collaborative large-scale genome sequencing effort to comprehensively identify rare risk and protective variants contributing to multiple common disease phenotypes.

Overview

The CCDG initiative explores a range of diseases with the goal of:

Undertaking variant discovery for enough different examples of disease architectures and study designs to better understand the general principles of genomic architecture underlying common, complex inherited diseases.
Understand how best to design rare variant studies for common disease.
Develop resources, informatics tools, and innovative approaches and technologies for multiple disease research communities and the wider biomedical research community.

The CCDGs study cardiovascular diseases (early-onset cardiovascular disease, atrial fibrillation, hemorrhagic stroke), neuropsychiatric diseases (autism, Alzheimer's disease, epilepsy), and immune-mediated diseases (irritable bowel disorder, asthma, Type-1 diabetes). CCDG studies have been limited to the nine selected diseases to increase study power.

The CCDGs collaborate with other projects, including the National Heart Lung and Blood Institute (NHLBI) Trans-omics for Precision Medicine program. The centers also receive co-funding from NHLBI.

We currently estimate that the CCDG program will sequence approximately 100K whole genomes and 125K whole exomes during the life of the program.

More information on the CCDGs, including publications, can be found on the Coordinating Center managed website: http://ccdg.rutgers.edu/.

Overview
The CCDG initiative explores a range of diseases with the goal of:

Undertaking variant discovery for enough different examples of disease architectures and study designs to better understand the general principles of genomic architecture underlying common, complex inherited diseases.

Understand how best to design rare variant studies for common disease.

Develop resources, informatics tools, and innovative approaches and technologies for multiple disease research communities and the wider biomedical research community.

The CCDGs study cardiovascular diseases (early-onset cardiovascular disease, atrial fibrillation, hemorrhagic stroke), neuropsychiatric diseases (autism, Alzheimer's disease, epilepsy), and immune-mediated diseases (irritable bowel disorder, asthma, Type-1 diabetes). CCDG studies have been limited to the nine selected diseases to increase study power.

The CCDGs collaborate with other projects, including the National Heart Lung and Blood Institute (NHLBI) Trans-omics for Precision Medicine program. The centers also receive co-funding from NHLBI.

We currently estimate that the CCDG program will sequence approximately 100K whole genomes and 125K whole exomes during the life of the program.

More information on the CCDGs, including publications, can be found on the Coordinating Center managed website: http://ccdg.rutgers.edu/.